The Indian Patent Office has approved pharmaceutical company Pfizer’s application to patent its Prevenar 13 (pneumococcal 7-valent conjugate) drug, despite claims by Médecins Sans Frontières (MSF) that it is too obvious.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, pneumonia, patent, MSF, Indian Patent Office